XenoFocus Participates in American Academy of Ophthalmology Conference... Presents Research Results on 'Habitual Age-related Macular Degeneration Candidate Substance'

Genofocus will unveil the preclinical research results of the wet age-related macular degeneration treatment 'GF103' at the world's largest ophthalmology and vision science conference.

On the 16th, Genofocus announced that it will participate in the world's largest ophthalmology conference, the '2024 ARVO (Association for Research in Vision and Ophthalmology)'.

ARVO is the top international conference in the fields of ophthalmology and vision science held annually in the United States. Ophthalmologists and researchers from around the world attend to share the latest research trends as well as basic and clinical research papers. This year, it will be held in Seattle, Washington, USA, from the 5th to the 9th of next month (local time).

At this event, Genofocus will present the excellent efficacy and safety demonstrated through preclinical research results of GF103, a treatment for wet age-related macular degeneration. The title of the presentation poster is 'GF103: An Orally Administered Bacillus Superoxide Dismutase in Clinical Development for Wet-AMD Treatment.'

GF103 is a high-purity protein drug candidate developed by modifying an antioxidant enzyme (Mn-SOD) discovered from Bacillus probiotics. It removes reactive oxygen species, which are the root cause of various chronic diseases, and is effective against a range of conditions including wet age-related macular degeneration, inflammatory bowel disease, and pulmonary fibrosis.

A Genofocus representative stated, "At this year's ARVO, we will present the preclinical efficacy and safety research results of GF103, a candidate for wet age-related macular degeneration, and also discuss clinical trials in Australia."

Dr. Jang In-ik, who led the overall clinical development at BiomeLogic, Genofocus's new drug development subsidiary, said, "Unlike existing ocular injections, GF103 can be administered orally, significantly improving treatment convenience for patients. We also confirmed that its excellent safety profile makes it an excellent combination therapy partner with other treatments." He emphasized, "Based on these preclinical results, we will validate the high value of GF103 with experts and seek various collaborative clinical research partners."